New questions and expanding possibilities
Fenbendazole’s research story is expanding into fungal infections, excessive tissue scarring, tissue preservation after injury and immune signaling.
The findings offer concrete reasons for scientific interest. Investigators have reported reduced fungal growth, less experimental lung fibrosis and improved movement after spinal cord injury in mice. Studies using human-derived cells have also identified changes in processes that contribute to scarring.
Recent publications add to that story. A 2025 antifungal screening study again identified activity against Cryptococcus, while a 2026 investigation examined whether fenbendazole could shift human liver cells away from an activated, scar-producing state.
These are laboratory and animal findings, including experiments with human-derived cells. They provide specific starting points for exploring how an existing compound might contribute to new treatment approaches.
Antifungal activity and Cryptococcus
Fungi are biologically distinct from parasitic worms. An antifungal finding therefore represents a separate research direction from fenbendazole’s established antiparasitic action.
One focus is Cryptococcus neoformans, a yeast capable of causing serious infection in people. Yeasts are single-celled fungi.
A 1994 study examined the susceptibility of Cryptococcus isolates to benzimidazole compounds, including fenbendazole. Some isolates came from clinical cases, allowing researchers to test organisms associated with human disease in controlled laboratory conditions.
Later work continued this direction. A 2020 study reported inhibition of 17 isolates of Cryptococcus neoformans and Cryptococcus gattii at low experimental concentrations and examined disruption of fungal microtubules.
Microtubules are structures that help cells organize their contents and carry out essential activities. Interfering with them can disturb fungal growth and survival.
These findings give the antifungal research a defined target: how fenbendazole affects the growth and survival of particular Cryptococcus species.
Following the antifungal mechanism
A 2024 study investigated the response of Cryptococcus neoformans to fenbendazole using proteomics, the large-scale study of proteins.
Proteins perform much of a cell’s work. Examining changes in their abundance can help identify which systems respond to a compound.
The researchers found changes involving metabolism, RNA processing and transport within fungal cells. They also identified protein kinases involved in susceptibility. Protein kinases help regulate cellular activity by modifying other proteins.
Fungal mutants lacking certain kinases were more resistant to fenbendazole. This adds evidence about the biological machinery involved, beyond observing that growth decreased.
The investigation also reported reduced fungal burden in mice receiving fenbendazole combined with amphotericin B, an established antifungal medicine. Fungal burden means the amount of fungus detected in the samples examined.
Together, the work connects fungal susceptibility, protein-level responses and a combination experiment in a living system. It supports further investigation of an anticryptococcal application.
Another antifungal finding in 2025
A study published in Letters in Applied Microbiology in March 2025 screened 27 medicines against strains of Cryptococcus neoformans and Cryptococcus gattii.
Fenbendazole was among the compounds that showed antifungal activity in the laboratory screening. The study adds a separate investigation to the earlier Cryptococcus findings.
Screening studies help identify compounds worth examining in greater depth. Alongside mechanism-focused research, they help build the case for investigating susceptibility, effective exposure and possible therapeutic applications.
Fibrosis and the biology of excessive scarring
Fibrosis means the excessive accumulation of scar-forming material in tissue.
Scar formation is part of repair. The difficulty arises when repair activity persists and produces too much connective material, changing the tissue’s structure and function.
Fibroblasts help maintain and repair tissues. Under certain signals, they can become more active myofibroblasts, cells that contract tissue and produce material such as collagen.
Collagen is a normal structural protein. Its excessive deposition contributes to fibrosis.
This makes the behavior of scar-producing cells an important research target. Scientists investigate whether modifying their activation, movement or production of collagen could limit pathological scarring.
Fenbendazole has been examined in this setting, with studies addressing both lung fibroblasts and liver cells involved in fibrosis.
Lung fibrosis in a 2022 study
A 2022 study in the International Journal of Molecular Sciences investigated fenbendazole in mice with bleomycin-induced lung fibrosis. Bleomycin is used experimentally to produce lung injury and scarring.
The investigators reported that fenbendazole reduced fibrosis in that model.
Their laboratory experiments also used human-derived lung fibroblasts. Fenbendazole inhibited their proliferation and migration, meaning cell multiplication and movement, and reduced their transition toward collagen-producing myofibroblasts.
The study connected these effects with glucose metabolism and signaling involving AMPK and mTOR. These systems help coordinate cellular energy status and growth.
The biological question is whether changing the activity and fuel processing of fibroblasts can reduce excessive scar formation.
The mouse findings and human-cell experiments provide complementary information: an effect on experimental scarring in a living system and insight into the behavior of human-derived scar-producing cells.
A new fibrosis direction in 2026
A study published in Liver International in July 2026 examined whether microtubule-targeting compounds could change the behavior of activated human hepatic stellate cells.
Hepatic means relating to the liver. Stellate cells can become major producers of scar-forming material during chronic injury.
Researchers screened 1,134 compounds and selected five for their cell-reprogramming effects. They reported that fenbendazole produced the strongest effect among those selected compounds, reducing activation-related markers and restoring features associated with cell-to-cell adhesion.
The finding raises a compelling question: can an activated, scar-producing cell be shifted toward a less fibrogenic state? Fibrogenic means contributing to fibrosis.
In the animal experiment, researchers administered febantel, a related compound converted into fenbendazole through metabolism. Febantel reduced fibrosis-related measurements in mice.
The human-cell and animal findings concern different administered compounds. Together, they support further investigation of how this molecular family might influence pathological scarring.
Spinal cord injury and secondary tissue damage
A spinal cord injury involves more than the immediate mechanical damage. Biological responses after the injury can influence how much tissue survives and how much function remains.
A study published online in 2013 and in a 2014 issue of Neuroscience examined fenbendazole exposure in a mouse spinal cord injury model.
The researchers reported improved locomotor function, meaning movement, and greater preservation of total tissue and white matter. White matter contains nerve fibers that carry signals between parts of the nervous system.
They also observed reduced B-cell-related signals and antibody staining at the injury site, suggesting a possible connection with the immune response.
The exposure occurred for four weeks before injury. Following injury, the animals received regular feed.
The favorable observations concern tissue preservation and functional recovery after prior exposure. They suggest a direction for investigating secondary injury mechanisms and provide a reason to ask whether benefits could also occur when exposure begins after injury. That would require a separate experiment.
Allergic airway inflammation
Inflammation is a coordinated response involving cells and chemical signals. In allergic disease, particular immune pathways can contribute to symptoms and tissue changes.
A 2009 study examined fenbendazole in a mouse model of asthma. The researchers reported reduced lung eosinophilia and Th2-related responses.
Eosinophilia means an increased presence of eosinophils, immune cells involved in some allergic reactions. Th2 refers to a pattern of immune activity associated with signals such as interleukin-5 and interleukin-13.
The experiment included exposure during early development, including before birth and after weaning. Additional laboratory work examined immune cells from allergic mice.
The reported reduction in allergic inflammation gives researchers a specific immune response to investigate further. The developmental exposure pattern is part of that finding and helps define how follow-up experiments would need to be designed.
Macrophages and inflammatory signaling
Macrophages are immune cells that respond to danger signals, clear material and help coordinate inflammation.
A 2025 study examined fenbendazole in RAW264.7 cells, a mouse macrophage cell line, including conditions stimulated with lipopolysaccharide, or LPS. LPS is a bacterial component commonly used to trigger inflammatory activity in experiments.
The investigators reported markedly reduced production of TNF-alpha, an inflammatory signaling protein, while IL-10 production continued. IL-10 helps regulate immune responses.
They also observed changes in immune-related surface markers. Reduced cellular survival and metabolic activity accompanied some findings, which matters when interpreting the lower inflammatory output.
These observations identify a focused next question: can inflammatory signaling be modified at exposures that preserve useful immune-cell function? Studying signaling and cell survival together would help clarify the potential value of the response.
Different biological goals
The immune findings involve selected cells, signals and responses.
In fungal infection, researchers may seek better control of an organism. In allergic inflammation, they may seek to moderate an excessive response. Following tissue injury, they may investigate whether changing particular immune activities preserves function.
The common thread is precision: identifying which response changes and whether that change improves a meaningful outcome. That gives immune research a more useful direction than a general claim of immune boosting.
Research directions worth following
The newer findings suggest several practical directions for further investigation.
Antifungal research can examine how consistently different Cryptococcus strains respond, how fenbendazole interacts with established antifungal medicines, and whether useful exposure can be achieved at the infection site.
Fibrosis research can test whether scar-producing cells remain less active after exposure ends, whether effects can be reproduced in additional models, and whether changes in collagen deposition improve organ function.
Spinal cord injury research can investigate administration after injury and distinguish effects on tissue preservation from effects on movement and immune signaling.
Immune-cell studies can examine whether changes in inflammatory signals persist at exposures that preserve cell survival.
These are research questions arising from published findings. They describe opportunities for follow-up, rather than announced human trials.
Connecting the findings with human health
Human-derived fibroblasts and hepatic stellate cells allow researchers to examine processes relevant to human tissue scarring. Clinical fungal isolates provide another connection by allowing organisms associated with human infections to be studied directly.
The broader development question is how an observed biological effect might become a useful treatment approach. That requires connecting effective exposure with reproducible benefit, tolerability and outcomes in people.
The findings give that work a starting point. They do not yet demonstrate clinical benefit for the conditions discussed here.
An expanding research story
The interest in fenbendazole beyond parasites and cancer rests on identifiable observations: susceptible fungal strains, changes in scar-producing cells, less experimental fibrosis, tissue preservation and altered immune responses.
The 2025 antifungal screening and 2026 liver-cell study add recent findings to this wider picture. They show that the subject includes new investigations as well as older observations worth revisiting.
Each direction has its own next question. Understanding how an effect works, reproducing it and testing its practical value are the steps through which a research possibility can develop.
Frequently asked questions
Has fenbendazole been investigated beyond parasites and cancer?
Yes. Published research includes antifungal activity, fibrosis models, experimental spinal cord injury and immune responses.
Which fungi are central to this research?
The studies discussed here focus on Cryptococcus neoformans and Cryptococcus gattii. Their findings concern those organisms and the tested strains.
Were people treated in the antifungal studies described here?
The research discussed includes fungal cultures and animal experiments. Clinical isolates came from patients, but testing those organisms is different from treating the patients.
What does antifibrotic mean?
It describes an effect that limits fibrosis, the excessive accumulation of scar-forming material. The fenbendazole findings discussed here come from experimental models and cell cultures.
Why are the human-cell findings interesting?
They allow researchers to examine processes involved in human tissue scarring, including the activation and behavior of fibroblasts and hepatic stellate cells.
When was fenbendazole given in the spinal cord injury study?
The mice received it before injury. Investigating exposure beginning afterward is a separate research opportunity.
Did the liver-fibrosis animal study use fenbendazole?
It used febantel, a related compound converted into fenbendazole. The same investigation examined fenbendazole directly in cultured human liver cells.
What does immune regulation mean in these studies?
It means changes in particular immune cells, signals or responses. The biological goal depends on the setting, such as moderating allergic inflammation or investigating secondary injury.
Are human trials announced for these applications?
The studies discussed here do not identify an announced human treatment trial for these applications. The follow-up directions describe research opportunities, not confirmed trial schedules.
Can these findings provide a human dose or treatment schedule?
No. Experimental exposure conditions identify research questions; they do not establish validated human treatment instructions.
Related wellness pages
Fenbendazole Explained — History, Uses and Human Research
Explore the origins and wider research history behind fenbendazole.
Fenbendazole and Human Parasites — Findings from Early Clinical Studies
Discover the separate clinical record involving identified human worm infections.
Fenbendazole and Cancer Cell Biology — Experimental Findings
Explore experimental research involving cancer-cell division, metabolism and survival.